Apollo Hospitals Reports Improved Earnings, Plans Business Demerger; Buy Ratings Maintained
Apollo Hospitals Enterprise reported improved EBITDA and better-than-expected quarterly performance, driven by its hospital and HealthCo segments. The company plans to demerge its Omnichannel Pharmacy, 24/7, and telehealth businesses into a new entity to unlock value. Research firms Prabhudas Lilladher and Motilal Oswal maintain buy ratings with target prices of INR 10,500 and INR 10,400, respectively. Market data shows Apollo Hospital's stock trading at INR 8,424 with a price-to-earnings ratio of 53.68 as of November 6, 2026.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (66/100). Lens Score 31/100.
Outlets measured: moneycontrol, moneycontrol, economictimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 6 Nov, 04:13 am. Other outlets followed.